SCYNEXIS, Inc. announced on September 4, 2025, that it would deliver multiple presentations highlighting data on its second-generation fungerp drug candidate, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12). The congress is scheduled for September 19-22, 2025, in Bilbao, Spain.
The six presentations at TIMM-12 will focus on SCY-247's significant potential to combat difficult, resistant Candida infections, including Candida auris. This demonstrates the compound's broad-spectrum activity and its relevance to critical unmet medical needs.
SCYNEXIS is developing SCY-247 to address serious and challenging issues in infectious disease, and the presented data provide encouraging evidence of its potential against life-threatening fungal infections. The company anticipates reporting results from its Phase 1 SAD/MAD trial of SCY-247 later in Q3 2025, marking an important next step for the program.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.